Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation

被引:24
|
作者
Bruserud, O [1 ]
Ulvestad, E
机构
[1] Univ Bergen, Haukeland Univ Hosp, Gade Inst, Med Dept,Div Hematol, N-5021 Bergen, Norway
[2] Univ Bergen, Haukeland Univ Hosp, Gade Inst, Dept Microbiol & Immunol, N-5021 Bergen, Norway
关键词
acute myelogenous leukemia; T lymphocytes; costimulation; cytokine;
D O I
10.1006/cimm.2000.1725
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The ability of acute myelogenous leukemia (AML) blasts to mediate costimulatory signals during T lymphocyte activation was investigated in an experimental model where monoclonal T cell populations were stimulated with standardized activation signals (anti-CD3, anti-CD2, and anti-CD28 monoclonal antibodies and phytohemagglutinin). Proliferative T cell responses were detected for all AML patients (n = 16) when irradiated leukemia blasts were used as accessory cells during activation, T cell cytokine release was also observed for all patients when nonirradiated AML accessory cells were used, and for most patients a broad cytokine response (interleukin (IL) 2, IL4, IL10, IL13, and interferon-gamma) was detected. However, both T cell proliferation and cytokine release showed a wide variation among AML patients, and T cell responsiveness was in addition dependent both on the nature of the activation signal and on differences between individual T cell clones. The accessory cell function of AML blasts showed no correlation with the release of any single immunomodulatory soluble mediator (IL1 beta, IL6, TNF-alpha, soluble IL2 receptors) or the expression of any particular adhesion/costimulatory membrane molecule (CD54, CD58, CD80, and CD86) by the blasts. However, blocking studies with anti-CD58 and anti-CD80/86 monoclonal antibodies demonstrated that both pathways can be involved when AML blasts are used as accessory cells, but the relative importance and the Anal effects of signaling through these pathways differ between AML populations. Although there is a wide interpatient variation, we conclude that for a majority of patients the native AML blasts can mediate adequate costimulatory signals needed for accessory cell-dependent T cell activation. (C) 2000 Academic Press.
引用
收藏
页码:36 / 50
页数:15
相关论文
共 50 条
  • [31] Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels
    Glenjen, NI
    Hatfield, K
    Bruserud, O
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (01) : 24 - 34
  • [32] Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
    D Behl
    L F Porrata
    S N Markovic
    L Letendre
    R K Pruthi
    C C Hook
    A Tefferi
    M A Elliot
    S H Kaufmann
    R A Mesa
    M R Litzow
    Leukemia, 2006, 20 : 29 - 34
  • [33] Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia
    Behl, D
    Porrata, LF
    Markovic, SN
    Letendre, L
    Pruthi, RK
    Hook, CC
    Tefferi, A
    Elliot, MA
    Kaufmann, SH
    Mesa, RA
    Litzow, MR
    LEUKEMIA, 2006, 20 (01) : 29 - 34
  • [34] Clinical significance of low protein phosphatase-1 activity of blasts in acute myelogenous leukemia with high white cell counts
    Nishikawa, M
    Yamamoto, M
    Watanabe, Y
    Kita, K
    Shiku, H
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (03) : 559 - 565
  • [35] Circulating cells and exosomes in acute myelogenous leukemia and their role in disease progression and survival
    Miyamoto, Kendi Nishino
    Bonatto, Diego
    CLINICAL IMMUNOLOGY, 2020, 217
  • [36] Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia
    Wendelbo, O
    Nesthus, I
    Sjo, M
    Paulsen, K
    Ernst, P
    Bruserud, O
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (08) : 740 - 747
  • [37] Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia
    Øystein Wendelbo
    Ingerid Nesthus
    Malvin Sjo
    Kristin Paulsen
    Peter Ernst
    Øystein Bruserud
    Cancer Immunology, Immunotherapy, 2004, 53 : 740 - 747
  • [38] Acquired Acute Myelogenous Leukemia after Therapy for Acute Promyelocytic Leukemia with t(15;17): a Case Report and Review of the Literature
    Betancourt-Garcia, Rafael D.
    Castro, Justiniano
    Fernandez, Adry C.
    Lopez-Enriquez, Alberto
    Fradera, Jean
    Pacheco, Eileen
    PUERTO RICO HEALTH SCIENCES JOURNAL, 2009, 28 (02) : 146 - 150
  • [39] The Construction and Identification of Induced Pluripotent Stem Cells Derived from Acute Myelogenous Leukemia Cells
    Zhu, Liang-Fang
    Chen, Qiu-Ru
    Chen, Shao-Zhen
    Wang, Ling-Yan
    Luo, Xiao-Feng
    Ren, Jin-Hua
    Yuan, Xiao-Hong
    Wu, Xue-Qiong
    Zeng, Yan-Ling
    Xiao, Min
    Chen, Yong-Quan
    Chen, Ying-Yu
    Lin, Min-Hui
    Wu, Zheng-Jun
    Chen, Zhi-Zhe
    Hu, Jian-Da
    Yang, Ting
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 41 (04) : 1661 - 1674
  • [40] T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)
    Astrid Marta Olsnes
    Dmitri Motorin
    Anita Ryningen
    Andrey Y. Zaritskey
    Øystein Bruserud
    Cancer Immunology, Immunotherapy, 2006, 55 : 830 - 840